IMMUNE DEFENCE - OCT 23 2026 - 22 MIN READ

Vitamin d3 k2 supplement: What the evidence shows

WRITTEN BY TOM

The case for pairing D3 with K2 is biologically coherent and backed by a growing body of clinical work, but the evidence is not uniform across outcomes. The strongest signal sits in bone and vascular calcification research. The immune-function data for D3 alone is well-established at the GB-NHC level. Where K2 adds to that picture, and how much, is still being worked out. Here is what the primary literature actually says.

D3 and K2 share overlapping biology in bone and vascular tissue, but most of the clinical trials are small and recent, the signal is real, the certainty is not yet settled.
From this read

Key facts

Vitamin D contributes to the normal function of the immune system, this is a GB-NHC authorised claim, authorised at a threshold of 15 µg/day.
A 2025 substudy RCT found that combined vitamin K2 and D3 supplementation may reduce systemic inflammation markers in patients with coronary artery calcification (Hasific et al. (2025)).
A 2022 paediatric RCT showed that combined K2 and native vitamin D supplementation may reduce vascular calcification progression in children on haemodialysis (El et al. (2022)).
Most combination trials to date are small (under 100 participants) and range from 12 weeks to 12 months, effect sizes are plausible but replication in larger cohorts is still needed.
Rōnin delivers 50 µg (2, 000 IU) of cholecalciferol from algal sources, the vegan form of D3, at a dose well above the GB-NHC authorisation threshold.

What the evidence actually shows

Start with what is solid. Hasific et al. (2025) published a substudy of a randomised controlled trial examining the effects of combined vitamin K2 and D3 supplementation on epicardial adipose tissue and systemic inflammation in patients with severe coronary artery calcification. The results suggest the combination may reduce inflammatory burden in this population, though the substudy design means I would not overstate the effect size until the full trial data is published.

The protocol underpinning that work was pre-registered and published separately by Hasific et al. (2023), which is useful because it lets you see exactly what was measured and why. The trial used MK-7 (menaquinone-7) as the K2 form and cholecalciferol as the D3 form. Those choices matter, and I will come back to them in the dosing section.

On the bone side, Minoretti et al. (2023) found that supplementation with vitamins D3 and K2 may increase serum levels of DKK-2, a biochemical marker associated with fragility fracture risk, in older adults. The sample was small and the clinical significance of the DKK-2 shift is still debated, but it points to a shared pathway between these two fat-soluble vitamins that goes beyond simple additive effects.

My honest read: the combination is not snake oil. The biology is coherent and the early RCT data is encouraging. But anyone selling you certainty on the exact magnitude of benefit is ahead of the evidence.

The biology: what is actually happening inside the cell

Vitamin D3 and K2 are both fat-soluble. They are absorbed via the same lymphatic pathway, and they share downstream targets in bone and vascular tissue. That shared biology is why researchers started combining them in the first place.

D3 (cholecalciferol) is converted in the liver to 25-hydroxyvitamin D, then in the kidneys to its active form, 1, 25-dihydroxyvitamin D (calcitriol). Calcitriol binds to the vitamin D receptor (VDR), which is expressed in over 35 tissue types, including immune cells. Through the VDR, vitamin D signalling influences the expression of genes involved in innate immune responses. This is the mechanistic basis for the GB-NHC authorised claim that vitamin D contributes to the normal function of the immune system.

K2's role is distinct but complementary. It acts as a cofactor for the enzyme gamma-glutamyl carboxylase, which activates vitamin K-dependent proteins by carboxylating glutamate residues. Two of those proteins are particularly relevant here: osteocalcin (which directs calcium into bone matrix) and matrix Gla protein (MGP, which inhibits calcium deposition in arterial walls). Without sufficient K2, both proteins remain undercarboxylated and functionally inert.

Here is where the combination logic becomes clearer. D3 upregulates the production of osteocalcin and MGP. K2 activates them. If you have adequate D3 but insufficient K2, you are producing more of these proteins without the cofactor needed to switch them on. Schröder et al. (2020) demonstrated in a 3D human bone spheroid model that K2 modulates the mechanical properties of bone tissue in a vitamin D-induced context, suggesting the two vitamins interact at the cellular level rather than simply adding together.

In vascular tissue, Florea et al. (2021) used Na[18F]F PET/MRI imaging in patients with carotid artery disease to examine what happens to calcification activity when D3 and K2 are combined. The imaging data suggested the combination may reduce active calcification in arterial tissue. This is early-stage evidence and the sample was small, but it is the kind of mechanistically-grounded imaging study that makes the hypothesis worth taking seriously.

If you want to go deeper on why these two vitamins are studied together rather than separately, I wrote a longer piece on the vitamin d3 k2 why take together question that covers the receptor-level evidence in more detail.

Dosing: what the clinical evidence actually used

This is where most supplement labels fall short. Knowing that D3 and K2 work together is not enough. The question is: at what dose, in what form, and for how long?

Vitamin D3

The trials that found meaningful effects on immune function and bone health have generally used doses between 25 µg (1, 000 IU) and 100 µg (4, 000 IU) daily. The GB-NHC authorised threshold for the immune-function claim is 15 µg/day. The UK Scientific Advisory Committee on Nutrition (SACN) reference nutrient intake is 10 µg/day for the general population, with a suggested upper limit of 100 µg/day for supplementation without medical supervision.

The form matters too. Cholecalciferol (D3) raises serum 25-hydroxyvitamin D more effectively than ergocalciferol (D2) over sustained periods. Most trials use cholecalciferol. Historically, cholecalciferol was derived from lanolin (sheep's wool), which made it unsuitable for vegans. Algal-derived cholecalciferol is chemically identical and performs identically in absorption studies, but it is worth confirming the source on any label you are reading.

A well-formulated product should state the form (cholecalciferol, not just "vitamin D"), the source (algal or lanolin), and the dose in micrograms, not just IU. Rōnin delivers 50 µg of cholecalciferol from algal sources, that is 2, 000 IU per daily dose, above the GB-NHC threshold and within the range used in the clinical literature, in a form that is appropriate for vegans and verifiable on the batch certificate.

Vitamin K2

K2 comes in several subtypes. MK-4 and MK-7 are the most studied. MK-7 has a substantially longer half-life in the bloodstream (approximately 72 hours versus 1 to 2 hours for MK-4), which means once-daily dosing is pharmacologically appropriate for MK-7 but not necessarily for MK-4 at equivalent doses.

The trials showing effects on carboxylation of MGP and osteocalcin have used MK-7 doses ranging from 90 to 360 µg/day. The Hasific et al. trials used MK-7. El et al. (2022), working in a paediatric haemodialysis population, used native vitamin D alongside K2 and found the combination may reduce vascular calcification progression over 12 months. The K2 form used in that study was MK-7.

When you are reading a label, the questions to ask are: is it MK-4 or MK-7? What is the dose in micrograms? Is it from a named, standardised source (such as natto-derived MK-7) or just listed as "vitamin K2"? A label that says "vitamin K2 (as menaquinone)" without specifying the subtype and dose is not giving you enough information to judge whether it matches what was tested.

Bone health: the most consistent evidence base

If I am being honest about where the combination evidence is strongest, it is in bone-related outcomes. The mechanistic story is clear (D3 drives osteocalcin production, K2 activates it), and the animal data has been consistent for over two decades. Hara et al. (2001) showed that combined treatment with K2 and an active vitamin D analogue reduced bone loss in ovariectomised rats more than either alone. More recently, Villa et al. (2026) examined the effect of vitamin K and calcium in bone loss in ovariectomised rats, adding to the picture of how these nutrients interact in skeletal tissue.

Varlıhan et al. (2026) found that vitamins K2 and D3 may enhance guided bone regeneration in rat calvarial bone defects, which is interesting from a tissue-repair angle, though the translation to human supplementation at typical doses requires caution. Animal models with surgical defects are not the same as everyday bone turnover in healthy adults.

The human data is less voluminous but directionally consistent. Omelka et al. (2021) examined combinations of calcium, alfacalcidol (an active vitamin D analogue), and K2 on bone parameters, adding to the body of work suggesting these nutrients interact in skeletal tissue. [GB-NHC] Vitamin D contributes to the maintenance of normal bones, that claim is authorised and solid. The additional contribution of K2 to that outcome is plausible and supported by mechanism, but the human RCT evidence base is still smaller than I would like before making strong efficacy claims about the combination specifically.

I wrote a broader piece on the vitamin d3 k2 combination that goes into the bone-density trial data in more depth if you want the full picture.

Vascular calcification: a more nuanced picture

This is the outcome area that generates the most excitement in D3/K2 research, and also the one where I want to be most careful about overstating things.

The hypothesis is that activated MGP (which requires K2) inhibits calcium from depositing in arterial walls. Low K2 status means undercarboxylated MGP, which means less inhibition of vascular calcification. Supplementing K2 alongside D3 (which drives MGP production) could, in theory, reduce calcification activity in arteries.

Florea et al. (2021) used imaging to examine this in a small group of patients with carotid artery disease. The results are intriguing. But small imaging studies in high-risk populations are a long way from demonstrating a cardiovascular benefit in the general population. I find the hypothesis compelling enough to include K2 in a formula. I would not use this evidence to make a cardiovascular health claim, and I do not.

Hasific et al. (2025) and the protocol behind it (Hasific et al. (2023)) represent the most methodologically rigorous work in this space to date. The full results of that trial will be worth watching. Until then, I think the honest position is: the mechanism is sound, the early data is encouraging, and the evidence is not yet sufficient to anchor a strong efficacy claim about the combination's effect on vascular outcomes in healthy adults.

Absorption and bioavailability: what affects how much you actually use

Both D3 and K2 are fat-soluble. That has two practical implications. First, they are better absorbed when taken with a meal containing fat. A study in cystic fibrosis patients, a population with fat malabsorption, by Nowak et al. (2022) examined fat-soluble vitamins in standard versus liposomal form enriched with K2. The liposomal form showed advantages in that specific malabsorption context. For most healthy adults without fat malabsorption issues, standard forms taken with food are adequate, and the liposomal premium is probably not necessary.

Second, fat-soluble vitamins accumulate in tissue over time. D3 has a relatively long half-life in the body, which is why once-daily dosing is standard. MK-7 (the preferred K2 subtype for supplementation) also has a long half-life, making once-daily dosing appropriate. MK-4 has a short half-life and would theoretically require multiple doses per day to maintain circulating levels, which is rarely how it is formulated in supplements.

One practical point: if you are taking a D3 K2 supplement in capsule or tablet form, take it with your main meal. Not because the evidence says it dramatically changes outcomes in healthy people, but because there is no downside and the absorption data modestly favours it.

There is also an interesting question about whether D3 and K2 compete for absorption or act synergistically at the absorption stage. The current evidence suggests they do not compete. They use different transport mechanisms and the interaction is downstream at the target tissue level, not at the gut wall.

Who is most likely to benefit from a D3 K2 supplement

Vitamin D insufficiency is genuinely common in the UK. Public Health England data suggests that around 1 in 5 adults has low vitamin D status, with the figure rising in winter months and in people with darker skin tones who live at northern latitudes. The case for D3 supplementation in the UK population is strong and well-supported by the SACN guidance.

K2 insufficiency is less well characterised in population data, partly because routine serum K2 testing is not standard clinical practice. Dietary K2 comes primarily from fermented foods (natto is the richest source, with some contribution from aged cheeses) and to a lesser extent from animal products. People who eat little of these foods may have lower K2 intake, though whether that translates to functionally relevant undercarboxylation of MGP and osteocalcin in healthy adults is not definitively established.

The populations where the combination evidence is most relevant are older adults (where bone turnover and vascular calcification are clinically significant concerns), people with chronic kidney disease (as in the El et al. (2022) paediatric haemodialysis study), and people with established cardiovascular calcification (as in the Hasific trials). For healthy younger adults, the case is more about maintaining adequate status than correcting a deficiency-related problem.

I also think it is worth noting that there is something genuinely interesting about the idea that two fat-soluble vitamins evolved to work together in overlapping biological pathways. I wrote about a loosely related idea in The Snail at the Bottom of the Lake, about how ecosystems (and biology more broadly) tend to be more interconnected than reductionist thinking suggests. It is not a direct analogy, but the pattern holds.

What to look for on a label

Most of the D3 K2 supplements on the market are not formulated to match what was tested in the clinical literature. Here is what I would check before buying anything in this category.

For D3: confirm it is cholecalciferol, not ergocalciferol. Confirm the dose in micrograms (the IU conversion is 40 IU = 1 µg, so 2, 000 IU = 50 µg). If you are vegan, confirm the source is algal-derived. A label that just says "vitamin D" without specifying D3 versus D2 is not giving you enough information.

For K2: confirm it is MK-7, not MK-4 (or at least that the subtype is stated). Confirm the dose in micrograms. A label that says "vitamin K2 complex" without specifying the subtype is a red flag. The dose should be somewhere between 90 and 200 µg MK-7 for it to sit within the range used in the better-designed trials.

The trials that found effects on carboxylation markers used MK-7 at doses of 90 to 360 µg/day alongside D3 at doses of 25 to 100 µg/day. A product that does not specify the K2 subtype, or that uses MK-4 at a dose that would require multiple daily administrations to maintain circulating levels, is not the thing that was tested in those studies.

Rōnin's D3 is specified as cholecalciferol from algal sources at 50 µg per daily dose, with the source and form printed on the batch certificate. That is the criterion first; the product meets it. The K2 specification follows the same logic: MK-7 form, dose within the evidence-supported range, stated on the label rather than hidden in a blend.

Frequently asked questions

Can I take a vitamin D3 K2 supplement every day?

Daily dosing is consistent with how the clinical trials have been run. Both D3 and K2 (as MK-7) have long half-lives, making once-daily supplementation appropriate. The SACN upper level for D3 without medical supervision is 100 µg/day; most supplements sit well below that. Hasific et al. (2025) ran daily dosing over an extended period without reported safety concerns.

Does vitamin D3 K2 supplementation actually support immune function?

Vitamin D contributes to the normal function of the immune system, this is a GB-NHC authorised claim for vitamin D3, authorised at 15 µg/day. The direct evidence for K2 specifically adding to immune outcomes is thin, and the human data on this is limited enough that I would be overstating it to claim otherwise. The immune-function case rests primarily on the D3 component.

What is the difference between MK-4 and MK-7 in a K2 supplement?

MK-7 has a half-life of approximately 72 hours versus 1 to 2 hours for MK-4, meaning MK-7 maintains more stable circulating levels with once-daily dosing. Most recent RCTs, including those by Hasific et al. (2023), have used MK-7. If a label does not specify the subtype, you cannot tell which form you are getting.

Should I take a D3 K2 supplement with food?

Both vitamins are fat-soluble, so absorption is modestly improved when taken alongside a meal containing dietary fat. Nowak et al. (2022) examined this in a fat-malabsorption context. For most healthy adults, taking the supplement with a main meal is a sensible habit, though the difference is unlikely to be dramatic at typical supplementation doses.

Is algal-derived vitamin D3 as effective as lanolin-derived D3?

Algal cholecalciferol is chemically identical to lanolin-derived cholecalciferol. Absorption and conversion to 25-hydroxyvitamin D appear equivalent in available data. The distinction matters for vegans and for people who want to verify the source on a batch certificate. The efficacy evidence does not distinguish between the two sources because they are the same molecule.

Does the evidence support using a D3 K2 supplement for vascular health?

The mechanistic case is sound: activated matrix Gla protein (requiring K2) may inhibit arterial calcification. Florea et al. (2021) found imaging-based evidence that the combination may reduce calcification activity in carotid artery disease patients. The evidence in healthy adults is much thinner, and no authorised health claim exists for this outcome.

My honest take

I take a D3 K2 supplement every day. Not because I am certain the K2 is doing something measurable for me personally, but because the biological rationale is sound, the emerging RCT data is directionally consistent, and the downside risk at sensible doses is negligible.

The D3 side of this is not really in question for me. I live in London. The sun is not reliable. [GB-NHC] Vitamin D contributes to the normal function of the immune system, and I want to maintain adequate status year-round. The algal source matters to me because I do not eat animal products, and I want to be able to verify the form on a batch certificate rather than take it on faith.

The K2 question is more interesting. I find the MGP activation story genuinely compelling. The idea that you could be producing more of a calcium-regulating protein (because D3 drives its expression) while simultaneously lacking the cofactor to switch it on is the kind of mechanistic gap that makes biological sense and is worth closing. Whether that translates to a measurable outcome in a healthy adult in their thirties is something I cannot tell you with confidence. The human data on this is still accumulating.

What I can tell you is that the trials worth paying attention to are the ones that specify the K2 subtype (MK-7, not a vague "K2 complex"), use doses within the range that has shown effects on carboxylation markers, and measure actual endpoints rather than just proxy biomarkers. The Hasific et al. work is the most methodologically serious I have seen in this space, and I will be watching the full trial results closely.

If you are buying a D3 K2 supplement, read the label carefully. Confirm the D3 is cholecalciferol. Confirm the K2 is MK-7 and that the dose is stated. If the label cannot answer those questions, the product is probably not the thing that was tested in the research you are reading about.

This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement regimen.

References (10 studies)

IMMUNE DEFENCE - 23 MINVitamin C zinc supplement UK powder: what works IMMUNE DEFENCE - 16 MINImmune support supplement UK daily: what holds up

← All journal articles

The morning note

One honest email a day, with the sunrise: the morning’s field note from the journal, a line to keep, and a quiet minute outside before the day starts. No discounts, no noise - unsubscribe any time.